AXGN
AxoGen, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +16.5% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 411.71K | $17.26M | n/a | n/a |
| Q2 2026 | 97 | +13 | 31.59M | $1.46B | +13 | −1 |
| Q1 2026 | 88 | +4 | 26.93M | $890.85M | +13 | −9 |
| Q4 2025 | 84 | +1 | 23.54M | $770.31M | +1 | n/a |
| Q3 2025 | 15 | 0 | 12.88M | $229.79M | +1 | −2 |
| Q2 2025 | 13 | -3 | 10.16M | $110.24M | n/a | −3 |
| Q1 2025 | 13 | +1 | 4.00M | $74.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 2.94M | $48.52M | +2 | −1 |
| Q3 2024 | 10 | +4 | 2.95M | $41.31M | +4 | n/a |
| Q2 2024 | 6 | n/a | 2.53M | $18.31M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.01M | +3.2% | $14.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 959.59K | +40.8% | $13.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 634.34K | +4.2% | $8.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 110.35K | New | $1.55M | 0.0% | New | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 77.00K | -48.1% | $1.08M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 70.99K | New | $995,308 | 0.0% | New | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 31.60K | +1.4% | $444,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 26.39K | New | $370,030 | 0.0% | New | 1 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 17.10K | New | $239,742 | 0.0% | New | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 8.44K | -89.5% | $118,385 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.55M | 0.0% |
| Arrowstreet Capital | $995,308 | 0.0% |
| Two Sigma Investments | $370,030 | 0.0% |
| Point72 Asset Management | $239,742 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 219 holders, 49.68M shares, $1.61B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.50K sh · $173,940
Director · 13.35K sh · $646,592
Officer · 67.50K sh · $3.20M
Director · 14.15K sh · $640,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology